Atul Ltd receives USFDA's approval for Dapsone facility

Atul Ltd, one of the flagship companies of Lalbhai Group, has received the US Food and Drug Administration (USFDA) approval for its Dapsone manufacturing facility located at Valsad, Gujarat. “This is to intimate that the Dapsone manufacturing facility located at Atul, Valsad, Gujarat has now been approved by the US FDA,” Atul Ltd said in a BSE filing.
 
Dapsone, also known as diaminodiphenyl sulfone, is an antibiotic commonly used in combination with rifampicin and clofazimine for the treatment of leprosy.
 
The company has two business segments, namely, life science chemicals and performance & other chemicals. The life science chemical segment comprises several manufacturing facilities which include Dapsone manufacturing facility, it added.